Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis, Multidrug-Resistant | 118 | 2024 | 930 | 22.860 |
Why?
|
Antitubercular Agents | 120 | 2024 | 1373 | 15.120 |
Why?
|
Tuberculosis | 60 | 2024 | 2001 | 10.040 |
Why?
|
Mycobacterium tuberculosis | 42 | 2024 | 1903 | 5.400 |
Why?
|
Tuberculosis, Pulmonary | 23 | 2023 | 831 | 4.400 |
Why?
|
Rifampin | 25 | 2024 | 339 | 4.160 |
Why?
|
Nitroimidazoles | 17 | 2022 | 117 | 3.960 |
Why?
|
Oxazoles | 16 | 2022 | 199 | 3.460 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 12 | 2021 | 85 | 2.930 |
Why?
|
Drug Resistance, Multiple, Bacterial | 11 | 2018 | 586 | 1.870 |
Why?
|
HIV Infections | 34 | 2024 | 17275 | 1.650 |
Why?
|
Contact Tracing | 4 | 2024 | 271 | 1.560 |
Why?
|
Rural Health Services | 6 | 2012 | 381 | 1.550 |
Why?
|
South Africa | 24 | 2023 | 1821 | 1.360 |
Why?
|
Isoniazid | 6 | 2022 | 283 | 1.360 |
Why?
|
Antibiotics, Antitubercular | 5 | 2021 | 99 | 1.250 |
Why?
|
Community Health Services | 7 | 2011 | 655 | 1.150 |
Why?
|
Health Services Accessibility | 18 | 2024 | 5403 | 1.110 |
Why?
|
AIDS-Related Opportunistic Infections | 4 | 2019 | 662 | 1.100 |
Why?
|
Lesotho | 11 | 2012 | 74 | 0.990 |
Why?
|
Qualitative Research | 11 | 2024 | 2976 | 0.990 |
Why?
|
Microbial Sensitivity Tests | 14 | 2023 | 1945 | 0.920 |
Why?
|
Humans | 205 | 2024 | 758381 | 0.820 |
Why?
|
Human Rights | 5 | 2021 | 308 | 0.800 |
Why?
|
National Health Programs | 3 | 2017 | 439 | 0.740 |
Why?
|
Long QT Syndrome | 2 | 2015 | 465 | 0.730 |
Why?
|
Drug Resistance, Bacterial | 3 | 2019 | 1055 | 0.710 |
Why?
|
Pyrazinamide | 3 | 2019 | 60 | 0.700 |
Why?
|
Latent Tuberculosis | 2 | 2022 | 224 | 0.700 |
Why?
|
Oxazolidinones | 2 | 2017 | 97 | 0.670 |
Why?
|
Family Characteristics | 1 | 2024 | 1000 | 0.660 |
Why?
|
Pregnant Women | 2 | 2021 | 562 | 0.650 |
Why?
|
Medication Adherence | 7 | 2024 | 2155 | 0.590 |
Why?
|
Health Personnel | 7 | 2023 | 3311 | 0.590 |
Why?
|
Program Evaluation | 5 | 2012 | 2490 | 0.570 |
Why?
|
Harm Reduction | 1 | 2018 | 145 | 0.570 |
Why?
|
Attitude to Health | 4 | 2020 | 2025 | 0.560 |
Why?
|
Medically Underserved Area | 2 | 2011 | 257 | 0.550 |
Why?
|
Ethambutol | 2 | 2016 | 59 | 0.540 |
Why?
|
Anti-Retroviral Agents | 4 | 2024 | 1780 | 0.510 |
Why?
|
Social Stigma | 2 | 2021 | 763 | 0.510 |
Why?
|
Georgia (Republic) | 6 | 2019 | 39 | 0.490 |
Why?
|
Microscopy | 1 | 2019 | 884 | 0.460 |
Why?
|
Child | 39 | 2023 | 79813 | 0.450 |
Why?
|
Peru | 16 | 2012 | 884 | 0.450 |
Why?
|
Aminosalicylic Acid | 1 | 2013 | 20 | 0.450 |
Why?
|
Tuberculin Test | 4 | 2022 | 206 | 0.440 |
Why?
|
Directly Observed Therapy | 7 | 2012 | 139 | 0.430 |
Why?
|
Delivery of Health Care | 5 | 2023 | 5331 | 0.420 |
Why?
|
Men's Health | 1 | 2012 | 73 | 0.410 |
Why?
|
Social Support | 3 | 2020 | 2153 | 0.410 |
Why?
|
Drug Therapy, Combination | 16 | 2024 | 6293 | 0.410 |
Why?
|
Breast Feeding | 1 | 2020 | 1355 | 0.400 |
Why?
|
Electrocardiography | 2 | 2015 | 6363 | 0.390 |
Why?
|
Medicine, African Traditional | 1 | 2011 | 29 | 0.390 |
Why?
|
Blood-Borne Pathogens | 1 | 2011 | 52 | 0.380 |
Why?
|
Sputum | 5 | 2019 | 502 | 0.380 |
Why?
|
Universal Precautions | 1 | 2011 | 34 | 0.380 |
Why?
|
Diagnostic Tests, Routine | 1 | 2017 | 787 | 0.380 |
Why?
|
Prisoners | 3 | 2012 | 314 | 0.380 |
Why?
|
Earthquakes | 1 | 2013 | 186 | 0.360 |
Why?
|
Drug Delivery Systems | 3 | 2021 | 2211 | 0.350 |
Why?
|
Mothers | 1 | 2020 | 2189 | 0.350 |
Why?
|
Patient-Centered Care | 5 | 2021 | 1415 | 0.330 |
Why?
|
Soccer | 1 | 2011 | 141 | 0.320 |
Why?
|
Adult | 53 | 2024 | 219916 | 0.320 |
Why?
|
Practice Guidelines as Topic | 4 | 2023 | 7377 | 0.320 |
Why?
|
Patient Satisfaction | 3 | 2020 | 3446 | 0.320 |
Why?
|
Professional Role | 1 | 2011 | 309 | 0.310 |
Why?
|
Drug Administration Schedule | 8 | 2024 | 4839 | 0.310 |
Why?
|
Mass Screening | 4 | 2020 | 5425 | 0.310 |
Why?
|
Female | 68 | 2024 | 390316 | 0.310 |
Why?
|
Compassionate Use Trials | 3 | 2017 | 50 | 0.310 |
Why?
|
Drug Resistance, Multiple | 3 | 2007 | 253 | 0.310 |
Why?
|
Treatment Outcome | 33 | 2024 | 64379 | 0.310 |
Why?
|
Quality of Health Care | 3 | 2019 | 4317 | 0.310 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2015 | 3990 | 0.300 |
Why?
|
Patients | 1 | 2014 | 904 | 0.300 |
Why?
|
Haiti | 3 | 2018 | 549 | 0.300 |
Why?
|
Clinical Protocols | 5 | 2023 | 1436 | 0.300 |
Why?
|
Interviews as Topic | 5 | 2024 | 2675 | 0.300 |
Why?
|
Models, Organizational | 1 | 2011 | 546 | 0.300 |
Why?
|
Aviation | 1 | 2008 | 49 | 0.300 |
Why?
|
World Health Organization | 6 | 2019 | 1312 | 0.290 |
Why?
|
Epidemics | 1 | 2013 | 512 | 0.280 |
Why?
|
Disease Outbreaks | 2 | 2016 | 1755 | 0.280 |
Why?
|
Disaster Planning | 1 | 2013 | 557 | 0.280 |
Why?
|
Nurse's Role | 2 | 2011 | 188 | 0.280 |
Why?
|
Transportation of Patients | 1 | 2008 | 174 | 0.280 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2012 | 611 | 0.280 |
Why?
|
Anti-HIV Agents | 3 | 2024 | 4504 | 0.270 |
Why?
|
Retrospective Studies | 39 | 2022 | 80170 | 0.260 |
Why?
|
Program Development | 6 | 2012 | 1297 | 0.260 |
Why?
|
Adolescent | 34 | 2024 | 87888 | 0.260 |
Why?
|
Needs Assessment | 1 | 2011 | 1141 | 0.250 |
Why?
|
Male | 58 | 2024 | 358742 | 0.250 |
Why?
|
Infection Control | 3 | 2020 | 982 | 0.240 |
Why?
|
Hospitalization | 1 | 2024 | 10653 | 0.230 |
Why?
|
Time Factors | 15 | 2020 | 39873 | 0.230 |
Why?
|
India | 5 | 2023 | 2329 | 0.230 |
Why?
|
Anti-Bacterial Agents | 3 | 2023 | 7403 | 0.220 |
Why?
|
Chemistry, Pharmaceutical | 2 | 2015 | 275 | 0.220 |
Why?
|
Community Health Nursing | 1 | 2003 | 23 | 0.220 |
Why?
|
Health Services Needs and Demand | 1 | 2011 | 1401 | 0.220 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2011 | 932 | 0.210 |
Why?
|
Tuberculosis, Meningeal | 1 | 2023 | 47 | 0.210 |
Why?
|
Occupational Diseases | 1 | 2011 | 1486 | 0.210 |
Why?
|
Research Design | 3 | 2019 | 6154 | 0.210 |
Why?
|
Russia | 7 | 2012 | 381 | 0.210 |
Why?
|
Communicable Disease Control | 3 | 2020 | 842 | 0.200 |
Why?
|
Social Environment | 1 | 2007 | 1022 | 0.200 |
Why?
|
Clinical Trials as Topic | 3 | 2023 | 7985 | 0.200 |
Why?
|
Corneal Ulcer | 1 | 2023 | 128 | 0.200 |
Why?
|
Poverty | 6 | 2007 | 2692 | 0.190 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2022 | 1895 | 0.190 |
Why?
|
Anthropology, Cultural | 2 | 2011 | 102 | 0.190 |
Why?
|
Social Justice | 2 | 2024 | 479 | 0.180 |
Why?
|
Health Policy | 2 | 2019 | 2675 | 0.180 |
Why?
|
Health Promotion | 1 | 2012 | 2202 | 0.180 |
Why?
|
Counseling | 3 | 2023 | 1541 | 0.180 |
Why?
|
Social Identification | 1 | 2020 | 107 | 0.170 |
Why?
|
Middle Aged | 24 | 2024 | 219560 | 0.170 |
Why?
|
Tuberculosis Vaccines | 1 | 2019 | 48 | 0.170 |
Why?
|
Internal Medicine | 2 | 2006 | 1048 | 0.160 |
Why?
|
Cooperative Behavior | 3 | 2011 | 1501 | 0.160 |
Why?
|
Young Adult | 16 | 2023 | 58808 | 0.160 |
Why?
|
Developing Countries | 8 | 2012 | 2866 | 0.160 |
Why?
|
Alcoholism | 1 | 2009 | 1964 | 0.160 |
Why?
|
Patient Acceptance of Health Care | 1 | 2012 | 3175 | 0.160 |
Why?
|
Treatment Failure | 4 | 2019 | 2640 | 0.160 |
Why?
|
Pseudomonas Infections | 1 | 2023 | 621 | 0.160 |
Why?
|
Infant | 9 | 2021 | 36054 | 0.160 |
Why?
|
Pregnancy | 7 | 2023 | 29742 | 0.150 |
Why?
|
Schistosomiasis haematobia | 1 | 2017 | 15 | 0.150 |
Why?
|
Ethionamide | 1 | 2017 | 11 | 0.150 |
Why?
|
Decision Making | 1 | 2011 | 3915 | 0.150 |
Why?
|
Yogurt | 1 | 2017 | 71 | 0.150 |
Why?
|
Child, Preschool | 15 | 2021 | 42058 | 0.140 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 1722 | 0.140 |
Why?
|
Disease Transmission, Infectious | 2 | 2020 | 557 | 0.140 |
Why?
|
Anthelmintics | 1 | 2017 | 82 | 0.140 |
Why?
|
Pulmonary Medicine | 1 | 2019 | 221 | 0.140 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2003 | 708 | 0.140 |
Why?
|
Cycloserine | 1 | 2017 | 118 | 0.140 |
Why?
|
Drug Resistance | 2 | 2021 | 1593 | 0.140 |
Why?
|
Football | 1 | 2022 | 502 | 0.140 |
Why?
|
Hyperbilirubinemia | 1 | 2016 | 74 | 0.140 |
Why?
|
Predictive Value of Tests | 4 | 2014 | 15225 | 0.140 |
Why?
|
Papua New Guinea | 1 | 2016 | 46 | 0.140 |
Why?
|
Drug Carriers | 1 | 2021 | 705 | 0.130 |
Why?
|
Europe, Eastern | 1 | 2016 | 72 | 0.130 |
Why?
|
Colony Count, Microbial | 1 | 2016 | 328 | 0.130 |
Why?
|
Self Care | 1 | 2021 | 794 | 0.130 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 3425 | 0.130 |
Why?
|
Milk, Human | 1 | 2020 | 483 | 0.130 |
Why?
|
Costs and Cost Analysis | 1 | 2021 | 1673 | 0.130 |
Why?
|
Early Diagnosis | 1 | 2020 | 1177 | 0.130 |
Why?
|
Genome, Bacterial | 1 | 2020 | 770 | 0.130 |
Why?
|
Nanotechnology | 1 | 2021 | 707 | 0.130 |
Why?
|
Cholecalciferol | 1 | 2020 | 549 | 0.120 |
Why?
|
Vaccination | 2 | 2019 | 3356 | 0.120 |
Why?
|
Case Management | 1 | 2016 | 272 | 0.120 |
Why?
|
Specimen Handling | 1 | 2019 | 707 | 0.120 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2005 | 2125 | 0.120 |
Why?
|
Dental Care for Chronically Ill | 1 | 2014 | 32 | 0.120 |
Why?
|
Dentist-Patient Relations | 1 | 2014 | 32 | 0.120 |
Why?
|
Home Care Services | 1 | 2021 | 647 | 0.120 |
Why?
|
Stomach | 1 | 2019 | 694 | 0.120 |
Why?
|
Injections | 1 | 2017 | 830 | 0.120 |
Why?
|
Milk | 1 | 2017 | 443 | 0.120 |
Why?
|
Hypersensitivity | 1 | 2023 | 1155 | 0.110 |
Why?
|
Rural Population | 4 | 2017 | 2253 | 0.110 |
Why?
|
Pharmaceutical Preparations | 2 | 2020 | 1090 | 0.110 |
Why?
|
Endpoint Determination | 1 | 2016 | 590 | 0.110 |
Why?
|
Dosage Forms | 1 | 2013 | 56 | 0.110 |
Why?
|
Complementary Therapies | 1 | 1997 | 486 | 0.110 |
Why?
|
Education, Medical, Graduate | 1 | 2005 | 2359 | 0.110 |
Why?
|
Technology, Pharmaceutical | 1 | 2013 | 84 | 0.110 |
Why?
|
Cohort Studies | 10 | 2022 | 41252 | 0.100 |
Why?
|
Communicable Diseases | 1 | 2021 | 877 | 0.100 |
Why?
|
Stereotyping | 1 | 2014 | 240 | 0.100 |
Why?
|
Patient Isolation | 1 | 2013 | 100 | 0.100 |
Why?
|
Internationality | 1 | 2018 | 1000 | 0.100 |
Why?
|
Diffusion of Innovation | 1 | 2017 | 728 | 0.100 |
Why?
|
Hospitals | 2 | 2023 | 3888 | 0.100 |
Why?
|
Drug Approval | 2 | 2016 | 809 | 0.100 |
Why?
|
Risk Assessment | 6 | 2020 | 23883 | 0.100 |
Why?
|
Geography | 1 | 2014 | 659 | 0.100 |
Why?
|
Incidence | 7 | 2019 | 21273 | 0.100 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 5484 | 0.100 |
Why?
|
Risk Factors | 13 | 2019 | 73806 | 0.100 |
Why?
|
Infertility, Female | 1 | 2017 | 759 | 0.100 |
Why?
|
Gloves, Protective | 1 | 2011 | 23 | 0.100 |
Why?
|
Physicians | 1 | 2009 | 4581 | 0.100 |
Why?
|
Lung Diseases | 1 | 2021 | 1910 | 0.090 |
Why?
|
Consultants | 1 | 2011 | 53 | 0.090 |
Why?
|
Age Factors | 4 | 2019 | 18357 | 0.090 |
Why?
|
Healthcare Disparities | 4 | 2024 | 3362 | 0.090 |
Why?
|
Drug Combinations | 1 | 2016 | 2020 | 0.090 |
Why?
|
Research | 1 | 2019 | 1976 | 0.090 |
Why?
|
Health Plan Implementation | 2 | 2011 | 336 | 0.090 |
Why?
|
Logistic Models | 6 | 2018 | 13276 | 0.090 |
Why?
|
Siberia | 1 | 2009 | 30 | 0.090 |
Why?
|
Caregivers | 1 | 2022 | 2224 | 0.090 |
Why?
|
Hearing Loss | 1 | 2017 | 780 | 0.090 |
Why?
|
Organizational Case Studies | 2 | 2007 | 301 | 0.090 |
Why?
|
Waiting Lists | 1 | 2014 | 762 | 0.090 |
Why?
|
Aged | 13 | 2023 | 168217 | 0.090 |
Why?
|
Vulnerable Populations | 2 | 2015 | 699 | 0.080 |
Why?
|
Homosexuality, Male | 1 | 1997 | 1329 | 0.080 |
Why?
|
Health Care Surveys | 2 | 2009 | 2432 | 0.080 |
Why?
|
Organizational Objectives | 1 | 2011 | 426 | 0.080 |
Why?
|
International Cooperation | 1 | 2015 | 1430 | 0.080 |
Why?
|
Cost of Illness | 2 | 2019 | 1936 | 0.080 |
Why?
|
Telemedicine | 3 | 2021 | 3018 | 0.080 |
Why?
|
Europe | 1 | 2016 | 3420 | 0.080 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1997 | 2197 | 0.080 |
Why?
|
Population Surveillance | 3 | 2019 | 2606 | 0.080 |
Why?
|
Culture | 1 | 2012 | 623 | 0.080 |
Why?
|
Financing, Personal | 1 | 2011 | 309 | 0.080 |
Why?
|
Emigration and Immigration | 2 | 2004 | 394 | 0.080 |
Why?
|
Thrombocytopenia | 1 | 2016 | 1172 | 0.080 |
Why?
|
Pneumonectomy | 1 | 2015 | 1111 | 0.080 |
Why?
|
Kidney Diseases | 1 | 2019 | 2083 | 0.080 |
Why?
|
Perception | 1 | 2014 | 1196 | 0.080 |
Why?
|
Dietary Supplements | 1 | 2020 | 3388 | 0.070 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 2569 | 0.070 |
Why?
|
Mental Health | 1 | 2021 | 3232 | 0.070 |
Why?
|
Quality of Life | 2 | 2021 | 13286 | 0.070 |
Why?
|
Air Ambulances | 1 | 2008 | 92 | 0.070 |
Why?
|
Internship and Residency | 2 | 2006 | 5865 | 0.070 |
Why?
|
Health Education | 1 | 2013 | 1049 | 0.070 |
Why?
|
Policy | 2 | 2024 | 509 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2020 | 12262 | 0.070 |
Why?
|
Prevalence | 5 | 2019 | 15646 | 0.070 |
Why?
|
Mutation | 2 | 2020 | 29915 | 0.060 |
Why?
|
Disease Management | 2 | 2015 | 2500 | 0.060 |
Why?
|
Interprofessional Relations | 1 | 2011 | 989 | 0.060 |
Why?
|
Administration, Oral | 1 | 2013 | 3993 | 0.060 |
Why?
|
Equipment Design | 1 | 2013 | 3507 | 0.060 |
Why?
|
Infant, Newborn | 3 | 2020 | 26182 | 0.060 |
Why?
|
Social Sciences | 1 | 2024 | 40 | 0.060 |
Why?
|
Moldova | 1 | 2024 | 14 | 0.060 |
Why?
|
Deafness | 2 | 2019 | 457 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8611 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2008 | 1829 | 0.050 |
Why?
|
Models, Educational | 1 | 2006 | 373 | 0.050 |
Why?
|
Community-Institutional Relations | 1 | 2004 | 208 | 0.050 |
Why?
|
Hypokalemia | 1 | 2004 | 152 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3076 | 0.050 |
Why?
|
Consensus | 2 | 2023 | 3099 | 0.050 |
Why?
|
Georgia | 1 | 2022 | 190 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3196 | 0.050 |
Why?
|
Alcohol Drinking | 2 | 2012 | 4020 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10146 | 0.050 |
Why?
|
Diagnosis, Differential | 2 | 2007 | 12951 | 0.050 |
Why?
|
Malawi | 1 | 2022 | 301 | 0.050 |
Why?
|
Gram-Negative Bacteria | 1 | 2023 | 272 | 0.050 |
Why?
|
Social Responsibility | 1 | 2004 | 386 | 0.050 |
Why?
|
Vitamin B 6 | 1 | 2022 | 233 | 0.050 |
Why?
|
Health Behavior | 1 | 2012 | 2615 | 0.050 |
Why?
|
Public Health | 2 | 2024 | 2658 | 0.040 |
Why?
|
Prisons | 1 | 2022 | 174 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2017 | 25953 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2012 | 12096 | 0.040 |
Why?
|
Severity of Illness Index | 3 | 2018 | 15785 | 0.040 |
Why?
|
Mental Health Services | 1 | 2011 | 1718 | 0.040 |
Why?
|
Patient Care Team | 1 | 2011 | 2504 | 0.040 |
Why?
|
Delphi Technique | 1 | 2023 | 829 | 0.040 |
Why?
|
Nomograms | 1 | 2021 | 237 | 0.040 |
Why?
|
Drug and Narcotic Control | 1 | 2020 | 145 | 0.040 |
Why?
|
Age Distribution | 2 | 2003 | 2882 | 0.040 |
Why?
|
Standard of Care | 1 | 2023 | 550 | 0.040 |
Why?
|
Political Systems | 1 | 2019 | 23 | 0.040 |
Why?
|
Molecular Epidemiology | 1 | 2021 | 469 | 0.040 |
Why?
|
Ventilators, Mechanical | 1 | 2021 | 287 | 0.040 |
Why?
|
House Calls | 1 | 2021 | 160 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10747 | 0.040 |
Why?
|
Methicillin Resistance | 1 | 1999 | 198 | 0.040 |
Why?
|
Sex Factors | 1 | 2012 | 10505 | 0.040 |
Why?
|
Armenia | 1 | 2018 | 15 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2012 | 5273 | 0.040 |
Why?
|
Masks | 1 | 2020 | 207 | 0.040 |
Why?
|
Schistosoma haematobium | 1 | 2017 | 13 | 0.040 |
Why?
|
Biological Specimen Banks | 1 | 2023 | 782 | 0.040 |
Why?
|
Electromyography | 1 | 2003 | 1388 | 0.040 |
Why?
|
Health Care Costs | 1 | 2011 | 3245 | 0.040 |
Why?
|
Sex Distribution | 1 | 2003 | 2283 | 0.040 |
Why?
|
Socioeconomic Factors | 3 | 2007 | 7817 | 0.040 |
Why?
|
Social Conditions | 1 | 1997 | 119 | 0.040 |
Why?
|
Drug Stability | 1 | 2017 | 290 | 0.040 |
Why?
|
Doxycycline | 1 | 2019 | 341 | 0.040 |
Why?
|
Biological Availability | 1 | 2017 | 390 | 0.030 |
Why?
|
Drug Resistance, Microbial | 1 | 2000 | 856 | 0.030 |
Why?
|
Child Nutrition Disorders | 1 | 2018 | 150 | 0.030 |
Why?
|
Patient Compliance | 2 | 2006 | 2685 | 0.030 |
Why?
|
Child Nutritional Physiological Phenomena | 1 | 2018 | 295 | 0.030 |
Why?
|
Physician-Patient Relations | 1 | 2009 | 3242 | 0.030 |
Why?
|
Cultural Characteristics | 1 | 1997 | 251 | 0.030 |
Why?
|
Health Priorities | 1 | 2019 | 375 | 0.030 |
Why?
|
Adaptation, Psychological | 2 | 2022 | 2629 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2019 | 961 | 0.030 |
Why?
|
Pseudomonas aeruginosa | 1 | 2023 | 1275 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2006 | 39060 | 0.030 |
Why?
|
Kenya | 1 | 2017 | 749 | 0.030 |
Why?
|
Massachusetts | 2 | 2005 | 8823 | 0.030 |
Why?
|
Boston | 1 | 2007 | 9304 | 0.030 |
Why?
|
HIV | 1 | 2021 | 1581 | 0.030 |
Why?
|
Goals | 1 | 2019 | 707 | 0.030 |
Why?
|
California | 1 | 1997 | 1419 | 0.030 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2005 | 2496 | 0.030 |
Why?
|
Curriculum | 1 | 2006 | 3717 | 0.030 |
Why?
|
Survival Analysis | 1 | 2005 | 10112 | 0.030 |
Why?
|
Adrenergic alpha-Agonists | 1 | 1993 | 177 | 0.030 |
Why?
|
BCG Vaccine | 1 | 2015 | 371 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2024 | 3561 | 0.020 |
Why?
|
Proportional Hazards Models | 3 | 2014 | 12440 | 0.020 |
Why?
|
Mental Disorders | 1 | 2011 | 6803 | 0.020 |
Why?
|
Malnutrition | 1 | 2018 | 639 | 0.020 |
Why?
|
Protein-Energy Malnutrition | 1 | 2012 | 188 | 0.020 |
Why?
|
Endemic Diseases | 1 | 2012 | 190 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2012 | 573 | 0.020 |
Why?
|
Age of Onset | 1 | 2018 | 3298 | 0.020 |
Why?
|
Comorbidity | 2 | 2018 | 10495 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2907 | 0.020 |
Why?
|
Symporters | 1 | 1993 | 360 | 0.020 |
Why?
|
Confidentiality | 1 | 2014 | 609 | 0.020 |
Why?
|
Africa, Southern | 1 | 2009 | 59 | 0.020 |
Why?
|
Nutritional Status | 1 | 2018 | 1607 | 0.020 |
Why?
|
Leadership | 1 | 2019 | 1371 | 0.020 |
Why?
|
Demography | 1 | 2014 | 1651 | 0.020 |
Why?
|
Prognosis | 2 | 2012 | 29558 | 0.020 |
Why?
|
Nanoparticles | 1 | 2021 | 1940 | 0.020 |
Why?
|
Swine | 1 | 2019 | 5892 | 0.020 |
Why?
|
Data Collection | 1 | 1997 | 3322 | 0.020 |
Why?
|
Periodicals as Topic | 1 | 2019 | 1462 | 0.020 |
Why?
|
Arrhythmias, Cardiac | 1 | 2018 | 2248 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2885 | 0.020 |
Why?
|
HIV Seronegativity | 1 | 2008 | 211 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2012 | 58681 | 0.020 |
Why?
|
Societies, Medical | 1 | 2019 | 3891 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2551 | 0.020 |
Why?
|
Trachea | 1 | 1993 | 1081 | 0.020 |
Why?
|
Imidazoles | 1 | 1993 | 1179 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2012 | 960 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2012 | 1475 | 0.020 |
Why?
|
Self Report | 1 | 2017 | 3712 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2011 | 927 | 0.020 |
Why?
|
Ambulatory Care | 2 | 2008 | 2768 | 0.020 |
Why?
|
Capreomycin | 1 | 2004 | 14 | 0.010 |
Why?
|
Pilot Projects | 1 | 2017 | 8554 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2013 | 6233 | 0.010 |
Why?
|
Retreatment | 1 | 2006 | 596 | 0.010 |
Why?
|
International Educational Exchange | 1 | 2004 | 49 | 0.010 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2007 | 488 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2006 | 15638 | 0.010 |
Why?
|
Lung | 1 | 2021 | 9985 | 0.010 |
Why?
|
Animals | 4 | 2019 | 167777 | 0.010 |
Why?
|
Inservice Training | 1 | 2004 | 375 | 0.010 |
Why?
|
Prospective Studies | 1 | 2006 | 54136 | 0.010 |
Why?
|
Drug Tolerance | 1 | 2003 | 367 | 0.010 |
Why?
|
Disease Progression | 1 | 2018 | 13468 | 0.010 |
Why?
|
United States | 2 | 2006 | 72140 | 0.010 |
Why?
|
Magnesium | 1 | 2004 | 809 | 0.010 |
Why?
|
Carrier Proteins | 1 | 1993 | 4937 | 0.010 |
Why?
|
Sampling Studies | 1 | 2000 | 614 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2021 | 20500 | 0.010 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2005 | 1348 | 0.010 |
Why?
|
Health Planning | 1 | 1998 | 231 | 0.010 |
Why?
|
Algorithms | 1 | 2017 | 13959 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2009 | 4353 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8530 | 0.010 |
Why?
|
Morals | 1 | 1998 | 289 | 0.010 |
Why?
|
Smoking | 1 | 2012 | 9042 | 0.010 |
Why?
|
Sodium Chloride Symporters | 1 | 1993 | 10 | 0.010 |
Why?
|
Imidazoline Receptors | 1 | 1993 | 13 | 0.010 |
Why?
|
Thromboxane-A Synthase | 1 | 1993 | 34 | 0.010 |
Why?
|
Guanabenz | 1 | 1993 | 6 | 0.010 |
Why?
|
Prazosin | 1 | 1993 | 95 | 0.010 |
Why?
|
Chloride-Bicarbonate Antiporters | 1 | 1993 | 103 | 0.010 |
Why?
|
Receptors, Adrenergic, alpha | 1 | 1993 | 146 | 0.010 |
Why?
|
Receptors, Drug | 1 | 1993 | 157 | 0.010 |
Why?
|
Isoproterenol | 1 | 1993 | 394 | 0.010 |
Why?
|
Second Messenger Systems | 1 | 1993 | 202 | 0.010 |
Why?
|
Clonidine | 1 | 1993 | 169 | 0.010 |
Why?
|
Iodine Radioisotopes | 1 | 1993 | 1032 | 0.010 |
Why?
|
Cyclic AMP | 1 | 1993 | 1455 | 0.000 |
Why?
|
Drug Interactions | 1 | 1993 | 1414 | 0.000 |
Why?
|
Epithelium | 1 | 1993 | 1605 | 0.000 |
Why?
|
Rabbits | 1 | 1993 | 4771 | 0.000 |
Why?
|
Antihypertensive Agents | 1 | 1993 | 2018 | 0.000 |
Why?
|
Epithelial Cells | 1 | 1993 | 3665 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1993 | 18942 | 0.000 |
Why?
|